PMI-21

N/A

Report date: 2025/11/24 17:31:42

NME

Base Information

Drug NamePMI-21

Drug Alias NameAstatine-211-Labeled Radiopharmaceutical Inhibitor(Precision Molecular)PMI-21PMI 21

ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Nuclides > Astatine > 211AtRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionProstate-Specific Membrane Antigen inhibitors

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPrecision Molecular Inc

China Registration ClassN/A

Develop Information

Active CompaniesPrecision Molecular Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A